SG Americas Securities LLC Grows Stock Position in Edwards Lifesciences Corporation $EW

SG Americas Securities LLC boosted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 2.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 593,482 shares of the medical research company’s stock after acquiring an additional 15,370 shares during the period. SG Americas Securities LLC owned 0.10% of Edwards Lifesciences worth $50,594,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in EW. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in Edwards Lifesciences by 7.0% in the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after buying an additional 9,069 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Edwards Lifesciences by 13.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after buying an additional 10,078 shares during the last quarter. Atlantic Union Bankshares Corp boosted its stake in Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after buying an additional 11,384 shares during the period. Washington Trust Advisors Inc. increased its position in shares of Edwards Lifesciences by 15.6% during the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after acquiring an additional 17,625 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp increased its position in shares of Edwards Lifesciences by 97.3% during the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after acquiring an additional 21,950 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 0.4%

Shares of EW stock opened at $81.65 on Wednesday. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a 50 day moving average price of $82.16 and a 200 day moving average price of $81.65. The stock has a market capitalization of $47.42 billion, a P/E ratio of 44.62, a price-to-earnings-growth ratio of 2.14 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same quarter last year, the company earned $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 12th. BTIG Research reiterated a “buy” rating and issued a $103.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Wednesday, January 21st. Wells Fargo & Company upped their price target on Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Finally, Canaccord Genuity Group set a $87.00 price target on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, December 17th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $96.14.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the transaction, the vice president directly owned 21,266 shares of the company’s stock, valued at $1,827,387.38. The trade was a 34.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the sale, the vice president owned 33,934 shares in the company, valued at approximately $2,897,284.92. This trade represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 61,718 shares of company stock valued at $5,236,281. 0.34% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.